Atrial fibrillation is the most common sustained rhythm disturbance. Thromboembolic events related to atrial fibrillation result in significant morbidity, mortality and increases in the cost of healthcare. Anticoagulants are pivotal agents for the prevention and treatment of thromboembolic disorders. The latest American College of Cardiology/American Heart Association guidelines recommend antithrombotic therapy to prevent thromboembolism for all patients with atrial fibrillation, except those with lone atrial fibrillation or contraindications. Vitamin K antagonists were first synthesized in 1948 and for the past six decades they have been the only agents used for long-term oral anticoagulant therapy. Although these drugs are effective, they have numerous limitations, which have led to the development of newer anticoagulant therapies. The emerging oral anticoagulant agents are target selective. They have predictable pharmacokinetic and pharmacodynamic parameters and do not require routine monitoring. They are not associated with significant food and drug interactions, and can be administered in simple fixed daily or twice daily doses. This article reviews the current literature on various targets for anticoagulant therapy and newer oral anticoagulants for atrial fibrillation.
Background
Atrial fibrillation (AF) is the most common sustained rhythm disturbance [American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC), 2006]. The prevalence of AF increases with age [Psaty et al. 1997; Krahn et al. 1995; Wolf et al. 1987] . About 1% of adults have AF while 10% of those over 80 years of age are affected [Go et al. 2001 ]. The affected number worldwide will grow as the population ages. An estimated 2.3 million people in North America and 4.5 million people in the European Union have paroxysmal or persistent AF [Go et al. 2001] . The number in the United States is projected to increase to 5.6 million by 2050 [Miyasaka et al. 2006 ].
Thromboembolic events related to AF result in significant morbidity, mortality and increases in the cost of healthcare. The rate of ischemic stroke among patients with nonrheumatic AF averages 5% per year, and is two to seven times that of people without AF [Levy et al. 1999; Krahn et al. 1995; Atrial Fibrillation Investigators, 1994; Wolf et al. 1991 Wolf et al. , 1987 Flegel et al. 1987] . Rheumatic heart-disease-related AF was shown to increase stroke risk by up to 17 times compared with age-matched controls in the Framingham Heart Study [Wolf et al. 1978] , and attributable risk was five times greater than in those with nonrheumatic AF [Wolf et al. 1991] .
Anticoagulants are pivotal agents for the prevention and treatment of thromboembolic disorders [Hirsh et al. 2001a, b] . As per the ACC/AHA/ ESC guidelines for the management of AF, antithrombotic therapy with vitamin K antagonists (VKAs) for stroke prevention in patients with AF requires at least one moderate risk factor, such as, age 75 years or over, hypertension, heart failure, impaired left ventricular systolic function (ejection fraction 35% or less or fractional shortening less than 25%), or diabetes mellitus (level of evidence A). A meta-analysis of six randomized trials comparing aspirin with a placebo found that aspirin reduced the incidence of stroke or transient ischemic attack (TIA) by 22% (95% confidence interval [CI] 238%); the absolute risk reduction for prevention was 1.5% per year [Hart et al. 2007 ]. The clinical pharmacology of aspirin in preventing atherothrombosis was reviewed recently [Fauler et al. 2009 ]. However, randomized trials have shown that aspirin is consistently and substantially less effective than warfarin, except in low-risk patients [Hart et al. 2007; McNamara et al. 2003; van Walraven et al. 2002; Stroke Prevention in Atrial Fibrillation II Study Group, 1994] . Patients with none of the above risk factors can be offered aspirin but those with one or more should be considered for anticoagulation. Options for anticoagulation of patients with AF include immediate-acting unfractionated heparin, low molecular weight heparin, and long-acting VKAs (warfarin) for treating and preventing thromboembolic disorders. Although the benefits are clear, a number of limitations are associated with these agents. In this article we review the literature on recent advances in oral anticoagulation therapy in patients with AF for the prevention of thromboembolic complications.
Limitations of traditional anticoagulants
VKAs were first synthesized in 1948 and for the past six decades they have been the only agents used for long-term oral anticoagulant therapy [Shapiro, 2003; Mueller and Scheidt, 1994] . VKAs prevent gamma carboxylation of prothrombin, factors II, VII, IX and X, and proteins C and S. They have halflives ranging from 8 to 44 h [Ufer, 2005; Ansell et al. 2004] . Maximal efficacy is only exhibited when all vitamin-K-dependent coagulation factors are inhibited, which occurs after 45 days of therapy.
Warfarin has been shown to be superior to placebo, aspirin, and aspirin plus clopidogrel for the prevention of stroke in patients with AF in several trials [Hart et al. 2007; Mant et al. 2007; Antithrombotic Therapy in Atrial Fibrillation Study Group, 2006; Writing ACTIVE Group, 2006; Pérez-Gó mez et al. 2004; Hellemons et al. 1999; Gulløv et al. 1998; Morocutti et al. 1997; EAFT Study Group, 1993; Ezekowitz et al. 1992; Connolly et al. 1991; Stroke Prevention in Atrial Fibrillation Study Group, 1991; Petersen and Boysen, 1990 ;
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990; Petersen et al. 1989] . Although these drugs are effective, they have numerous limitations. VKAs act by lowering the functional levels of the vitamin-K-dependent clotting factors but the rates and extent of their effect on these factors are variable and cannot be predicted. The effect of heparin is also variable and cannot be predicted because of several factors, including variable bioavailability from subcutaneous absorption, occupation of binding sites by substances other than antithrombin, reduced ability to inactivate thrombin bound to fibrin and factor Xa (FXa).
Together, all of these factors lead to the need for frequent coagulation monitoring and dose adjustments that may adversely affect clinical efficacy. Data from randomized controlled clinical trials suggest that, despite close monitoring, only 5060% of patients on warfarin therapy have an international normalized ratio (INR) in the therapeutic range and the rest are either under or overtreated [Hart et al. 2007; Connolly et al. 2006; Albers et al. 2005 ; Executive Steering Committee of the SPORTIF III Investigators, 2003; Bradley et al. 2000; Bungard et al. 2000 ]. Monitoring is inconvenient for patients and physicians, and it often leads to underuse of these drugs. Thus the investigation continues to search for newer drugs that are simpler to administer, have more predictable effects, are more specific in action and can be given in fixed doses without the need for monitoring or with minimal requirement for monitoring.
Newer oral agents for anticoagulant therapy
The coagulation cascade is a series of proteolytic events mainly localized to the surface of activated platelets. Novel anticoagulants are designed to target specific enzymes or steps in the coagulation pathway. They have been developed from hematophagous organisms with recombinant DNA technology, or by structure-based drug design [Weitz and Hirsh, 2001] . These agents are being developed to overcome the inadequacies of warfarin and are expected to be as effective as warfarin, but with more favorable side-effect profiles. Broadly speaking, these agents are procoagulant complex specific and belong to one of the following groups: direct thrombin inhibitors (DTIs), FXa inhibitors, factor IX inhibitors, tissue factor inhibitors and novel VKAs. However, drugs in advanced development are targeting FXa or thrombin since their central location in the common coagulation pathway blocks both intrinsic and extrinsic pathways.
Thrombin as a target
Thrombin is a serine protease that converts fibrinogen to fibrin in the final steps of the coagulation cascade. Thrombin also activates factor XI, factor XIII and platelet protease activated receptors (PAR-1 and PAR-4) [Nutescu et al. 2008] . Moreover, since thrombin amplifies its own generation by activating factors VIII and V, limiting its activity becomes a vital mechanism to achieve effective anticoagulation [Bauer, 2006] .
Direct thrombin inhibitors X-ray crystallography has shown that thrombin has a deep groove on one side of the molecule, and the active site of the enzyme is buried deep within this groove [Grutter et al. 1990; Rydel et al. 1990 ]. In addition to the active site, there are two important positively charged patches at opposite poles on the thrombin molecule (exosite I and exosite II) which bind to macromolecular ligands [Sheeha and Sadler, 1994; Grutter et al. 1990; Rydel et al. 1990 ]. DTIs directly inhibit the active site of thrombin and exosite I [Hirsh and Weitz, 1999] while indirect thrombin inhibitors interact with exosite II and antithrombin to inhibit thrombin. Unlike heparin, DTIs inactivate fibrin-bound thrombin, as well as fluid-phase thrombin [Weitz and Buller, 2002; Weitz and Crowther, 2002] . This clot-bound thrombin acts as an important thrombogenic stimulus causing thrombus growth and clot propagation [Agnelli et al. 2005 ]. Thus, DTIs have an intrinsic pathophysiological advantage over VKAs. DTIs are not metabolized by the cytochrome P-450 (CYP) system and have limited binding to plasma proteins and cellular elements. Two oral DTIs have been studied in AF: ximelagatran and dabigatran. Ximelagatran was the first oral thrombin inhibitor but was rejected by the US Food and Drug Authority because of hepatotoxicity and subsequently withdrawn from the market.
Dabigatran
Dabigatran is an oral prodrug of dabigatran etexilate and is a potent, competitive and reversible inhibitor of thrombin. The conversion of dabigatran to dabigatran etixalate is carried out by a serum esterase that is independent of CYP and makes it less susceptible to dietary and drug interactions and to genetic polymorphisms that affect warfarin. However, dabigatran does have important drug interactions. P-glycoprotein inhibitors, including verapamil, amiodarone and especially quinidine, raise dabigatran serum concentrations considerably. This may elevate the risk of hemorrhage in such patients.
Dabigatran is administered once or twice daily. It has a 2 h onset and 1417 h halflife [Gross and Weitz, 2008] . Dabigatran is contraindicated in severe renal disease patients and interacts with proton pump inhibitors. Like ximelagatran, it offers the advantage of producing a predictable anticoagulant response, thereby eliminating the need for coagulation monitoring. However, unlike ximelagatran, dabigatran does not appear to carry hepatotoxic potential, with transaminase elevation seen in less than 1% of the population [Connolly et al. 2009; Wallentin et al. 2005] . A short summary of the published trials of dabigatran in patients with AF is given in Table 1 .
Prevention of Embolic and Thrombotic events in patients with persistent AF (PETRO) [Ezekowitz et al. 2007 ] was a double-blind, phase II, dose-escalating trial in which patients were randomized into 10 groups. Dabigatran doses (50, 150 and 300 mg twice daily) were combined in a three-by-three factorial fashion with aspirin (no aspirin, 81 mg or 325 mg aspirin once daily) and compared with warfarin alone (INR adjusted 23) for 12 weeks. The primary safety outcome was the incidence of composite bleeding or a thromboembolic event. The study was prematurely terminated for the group receiving aspirin (81 or 325 mg) plus dabigatran 300 mg because of excessive bleeding. A dose-dependent increase in bleeding was found in the dabigatran 150 mg and 300 mg groups compared with the 50 mg groups (p ¼ 0.0002, p ¼ 0.01, respectively) [Connolly et al. 2009 ]. Consequently, PETRO recommended dabigatran 150 mg twice daily for the phase III RE-LY trials because its concomitant use with aspirin did not cause increased bleeding. et al. 2009 ] was a phase III multicenter, randomized, non-inferiority trial. This trial enrolled 18,113 patients who had AF and were at a risk of stroke. Two dosages of dabigatran (110 mg and 150 mg twice daily), administered in a blinded fashion, were compared with adjusted-dose warfarin, administered in an unblinded manner. The median duration of the follow-up period was 2 years. . This difference was mostly because of a decrease in the rate of stroke with an ischemic or unspecified cause, whereas rates of hemorrhagic stroke were similar in the two dabigatran groups. There was no significant difference in the rates of death from vascular causes or any other cause between the two doses. However, compared with the 110 mg dose of dabigatran, the 150 mg dose was associated with an increased risk of major bleeding (p ¼ 0.052) and also with an increased risk of minor bleeding, including gastrointestinal bleeding. Thus, compared with warfarin, the 110 mg dose of dabigatran was associated with similar rates of stroke and systemic embolism and lower rates of major hemorrhage; the 150 mg dose of dabigatran was associated with lower rates of stroke and systemic embolism but with a similar rate of major hemorrhage.
RE-LY [Connolly
In the RE-LY trial [Connolly et al. 2009 ], dyspepsia was significantly more common with dabigatran than with warfarin, occurring in 348 (5.8%) patients in the warfarin group and in 707 (11.8%) and 688 (11.3%) patients in the 110 mg and 150 mg dabigatran groups, respectively (p < 0.001 for both comparisons).
The mechanism of action for increased dyspepsia among patients receiving dabigatran is currently unknown. The number of patients who died and had an acute coronary syndrome or an elevation of the alanine aminotransferase or the aspartate aminotransferase level exceeding three times the upper limit of normal while taking the study drug did not differ significantly between the treatment groups. The number of patients with elevations in the serum aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal did not differ between treatment groups and was about one third of the number associated with ximelagatran [Gage, 2009; Albers et al. 2005; Olsson et al. 2003 ]. However, patients who had a creatinine clearance of less than 30 ml/min or liver disease were excluded from RE-LY.
Ongoing trials include a phase III study evaluating dabigatran's role in cerebrovascular accident prevention in AF (RE-LYABLE) [ClinicalTrials.gov: NCT00808067], and a phase II dose-finding study in acute coronary syndrome prevention for patients on dual-platelet therapy (RE-DEEM) [ClinicalTrials.gov: NCT00621855]. RELY-ABLE extends anticoagulation treatment in RE-LY patients with dabigatran or warfarin for 28 months.
Factor Xa as target FXa acts as the convergence point for the intrinsic and extrinsic coagulation pathways and this makes it a crucial target for effective anticoagulation. FXa catalyzes the conversion of prothrombin to thrombin, with each molecule of FXa resulting in the generation of over 1000 thrombin molecules. The inhibition of FXa prevents this burst of thrombin and consequently diminishes thrombin-mediated activation of coagulation and platelets [Perzborn et al. 2005] . Moreover, FXa has been shown to activate clotting over a wide concentration range in vitro, which suggests that FXa inhibitors may have a wide therapeutic window.
Factor Xa inhibitors
Oral FXa inhibitors bind to the active site of both free and clot-bound FXa and block its thrombin interaction. Several orally active direct FXa inhibitors are currently in development. In general, as a class of new anticoagulants, they all have rapid onset of action, with peak anticoagulant effect achieved within 24 h, thus potentially obviating the need for a parenteral anticoagulant (unfractioned heparin or low molecular weight heparin) in the initial treatment. Among oral agents, rivaroxaban and apixaban are in phase III development and betrixaban is at an earlier stage. Besides these, LY517717, YM150, DU-176b, 813893, AVE-3247, EMD-503982, KFA-1982 and PRT054021 are all oral agents in clinical development for the prevention of thromboembolism in patients with AF [Agnelli et al. 2007; Eriksson et al. 2007; Zafar et al. 2007; Iwatsuki et al. 2006; Fukuda et al. 2004; Furugohri et al. 2004] .
Rivaroxaban
Rivaroxaban is a potent antithrombotic agent with over 10,000-fold greater selectivity for FXa than other serine proteinases, and inhibits both free and clot-bound FXa as well as prothrombinase Perzborn et al. 2005 ]. Rivaroxaban is administered as a fixed once daily dose and achieves peak plasma concentrations within 4 h after oral administration, with a terminal halflife ranging from 5 to 9 h [Kubitza et al. 2005 ]. It has a relative oral bioavailability of 80% and dual excretion via both the biliary (28%) and renal (66%) routes. Rivaroxaban was shown to have predictable dose-proportional pharmacokinetics and pharmacodynamics in phase I studies and dosing was not influenced by gender or body weight. Its absorption was moderately increased by coadministration of food [Kubitza et al. , 2006 . Rivaroxaban is partially metabolized by CYP3A4 and its elimination is impaired if given with strong CYP3A4 inhibitors like macrolides and ketoconazole. When cases of bleeding need reversal of effect, this can be achieved by recombinant FXa derivative [Lu et al. 2008 ], recombinant factor VIIa [Gruber et al. 2008] or by activated prothrombin complex concentrate [Gruber et al. 2008 ].
ROCKET AF is an ongoing phase III trial comparing rivaroxaban with warfarin for stroke prevention in patients with nonvalvular AF. Rivaroxaban at a dosage of 20 mg once daily is compared with INR-adjusted oral warfarin in a double-blind, double-dummy prospective randomized trial. Patients with a reduced creatinine clearance between 30 and 49 ml/min receive a reduced dose of 15 mg rivaroxaban once daily. Over 14,000 patients have been randomized at 1100 sites across 45 countries, and will be followed until 405 primary outcome events are observed. The primary composite outcome event is embolic and nonembolic stroke and non-central nervous system (CNS) systemic embolism. The secondary outcome endpoints are a composition of stroke, non-CNS systemic embolism, and vascular death [ROCKET AF Study Investigators, 2010; ClinicalTrials.gov: NCT00403767].
Another prospective, randomized, double-blind phase III trial in Japan is investigating the efficacy and safety of rivaroxaban for the prevention of stroke and embolism in 1200 patients with nonvalvular AF. This trial will compare a dosage of 15 mg rivaroxaban daily (patients with a creatinine clearance between 30 and 45 ml/min will receive 10 mg) with INR-adjusted warfarin for 12.5 years. The primary outcome composite endpoint is major and nonmajor clinically relevant bleeding and a composite of stroke and non-CNS systemic embolism. The secondary outcome endpoints are major and minor bleeding events, and any other adverse events, as well as the composite outcome of stroke, non-CNS systemic embolism and vascular death [ClinicalTrials.gov: NCT00494871].
Apixaban
Apixaban (BMS-562247) is a selective direct FXa inhibitor administered twice daily. Apixaban is a derivative of razaxaban, a direct FXa inhibitor with selectivity for both free and prothrombinase-bound FXa [Pinto et al. 2007 ]. It has an onset of 3 h onset and a halflife of 815 h [Carreiro and Ansell, 2008] . It is well tolerated for patients with renal and liver disease. Apixaban is partially metabolized by CYP3A4 and its elimination is impaired if given with strong CYP3A4 inhibitors (e.g. ketoconazole). There have been no previous studies with apixaban in patients with AF and dosing allocation is derived from previous studies on prevention and treatment of venous thromboembolism.
The Apixaban for Reduction In Stroke and Other Thromboembolic Events in AF (ARISTOTLE) study is a randomized, double-blind phase III trial for the prevention of stroke in patients with nonvalvular AF and at least one risk factor for stroke [ClinicalTrials.gov: NCT00412984] . This trial will evaluate the efficacy and safety of a dosage of 10 mg apixaban twice daily versus warfarin for the prevention of stroke and systemic embolism. Patients with a creatinine clearance less than 30 ml/min, aged over 85 years, and with a body weight less than 60 kg receive a dosage of 5 mg apixaban twice daily. Secondary outcome measures are confirmed ischemic stroke, hemorrhagic stroke, systemic embolism and all-cause death.
AVERROES is another phase III prospective, randomized, double-blind, superiority clinical trial comparing apixaban with aspirin in more than 5600 patients who are ineligible for warfarin for the prevention of stroke with a follow up of up to 3 years. Patients are randomized to a dosage of 5 mg apixaban twice daily versus acetylsalicylic acid at 81324 mg daily in a double-blind design. A dosage of 2.5 mg apixaban twice daily is given to patients if two of the following characteristics are present: age over 80 years, creatinine greater than 1.5 mg (133 mmol), and body weight less than 60 kg [ClinicalTrials.gov: NCT00496769].
YM150
YM150 is a synthetic FXa inhibitor that inhibits prothrombin activation induced by free FXa, prothrombinase and whole-blood clots. YM150 and its active metabolite YM222714 demonstrated potent antithrombotic effects in animal models of venous and arterial thrombosis at doses that did not prolong bleeding time. In phase I studies the drug has been shown to be well tolerated with predictable pharmacokinetics and pharmacodynamics in healthy volunteers. Food was not found to interfere with the absorption of YM150. Pharmokinetic effects correlated with pharmacodynamic effects, and a doseresponse relationship between YM150 and pharmacodynamics was observed [Eriksson et al. 2009; Iwatsuki et al. 2006 ]. 'Direct FXa inhibitor YM150 for prevention of stroke in subjects with nonvalvular AF a double blind, parallel, dose-finding study in comparison with open label warfarin' is a recently completed but unpublished multicenter, randomized, double-blind, double-dummy, multiple-dose, active control (dose-adjusted warfarin) parallel group study that aimed to determine the optimal tolerable dose of YM150 using 30 mg twice daily, 60 mg every day or twice daily, and 120 mg daily compared with warfarin. Patients were stratified by prior anticoagulant use (such as warfarin or heparin use within 8 weeks prior to baseline visit). Patients with paroxysmal, persistent or permanent nonvalvular AF with a stroke risk stratification score (CHADS2) of 16, and who had not had a recent (within 12 months) stroke or TIA were eligible. The primary outcome measure is incidence of major and clinically relevant nonmajor bleeding events during the treatment period. The absolute composite incidence as well as the absolute individual incidences of ischemic strokes, TIAs, systemic thromboembolic events, acute coronary syndromes, and all deaths during treatment will be provided along with their exact 95% CI (binomial distribution). The same estimates will also be provided separately by prior anticoagulant use [ClinicalTrials.gov: NCT00448214].
DU-176b
DU-176b is a highly specific FXa inhibitor with rapid oral absorption. DU-176b is absorbed within 2 h, with a plasma halflife of 8.610.7 h, and it is cleared mainly through the kidneys. Zafar and colleagues (2007) evaluated the antithrombotic effect in a phase I study by an ex vivo thrombus model, and under arterial conditions compared with baseline there was 26% and 17% reduction in thrombus size at 1.5 and 5 h, respectively (p < 0.05). Thrombin generation decreased by 28% at 1.5 h and 10% at 5 h. Changes in prothrombin time (PT) and INR correlated well with plasma drug concentrations (r ¼ 0.79 and 0.78). Pharmacological analyses showed that DU-176b was scarcely metabolized and suggested the potential for convenient alternate-day dosing [Fukuda et al. 2004 ].
Weitz and colleagues conducted a double-blind, double-dummy phase II study aiming to assess the safety of different dose regimens of DU-176b in 1146 patients with nonvalvular AF and a CHADS2 index of at least 2. Patients were randomly assigned to oral dosages of 30 mg every day, 30 mg twice daily, 60 mg every day or 60 mg twice daily DU-176b or warfarin (INR adjusted 23) for 12 weeks. The primary outcomes were the occurrence of major and/or clinically relevant nonmajor bleeding events. Secondary outcomes included major adverse cardiovascular events, a composite of stroke, systemic embolism, acute myocardial infarction, hospitalizations caused by cardiovascular conditions or cardiovascular death, as well as all other adverse events, including all bleeding events. The results of this trial suggest that dosages of 30 mg and 60 mg DU-176b daily are safe and well tolerated .
ENGA GE-AF TIMI-48 [ClinicalTrials.gov: NCT00781391] is an ongoing randomized, Therapeutic Advances in Cardiovascular Disease 4 (6) double-blind, double-dummy, multicenter study evaluating the efficacy and safety of DU-176b versus warfarin in 16,500 patients with AF over 24 months. Primary outcome measures are the composite endpoint of stroke and systemic embolic events. Secondary outcome measures are the composite clinical outcome of stroke, systemic noncerebral embolism, and all-cause mortality and major bleeding events.
Other agents
Tissue factor activation is the primary step in the initiation and sequential amplification of proteolytic activity that leads to thrombus formation [Steffel et al. 2006; Ragni et al. 1996 ]. The recombinant form of tissue factor pathway inhibitor, the physiologic inhibitor of the tissue factor/factor VIIa complex, is being tested, and there are also specific tissue factor/factor VIIa and FVIIa inhibitors (nematode anticoagulant protein) undergoing development [Giugliano et al. 2007; Lee et al. 2001; Presta et al. 2001; Stassens et al. 1996 ]. However, no oral agents have achieved sufficient refinement to be tested in clinical settings. The primary reason for this is low oral bioavailability via gastrointestinal absorption of any inactive prodrug, or decreased plasma activity of agents that have good oral bioavailability [Shirk and Vlasuk, 2007] .
Factor IX serves as a conduit between tissue factor-bearing cells and platelets and hence remains an invaluable link between the initiation and propagation phases of clot formation. Also studies suggest that factor X activation by the factor IXa/VIIIa pathway is more efficient and potent than the alternative tissue factor/factor VIIa-mediated extrinsic pathway of factor X activation [Lawson and Mann, 1991] . TTP889 is the only oral agent that has undergone extensive preclinical testing and was found to be as equally efficacious as heparin without a significant impact on bleeding [Rothlein et al. 2005] . Clinical development of TTP889 is limited to phase I studies at single and multiple doses with demonstration of a predictable pharmacokinetic profile and a halflife of 20 h. TTP889 has recently entered the factor IX inhibition in thrombosis prevention (FIXIT) trial [ClinicalTrials.gov: NCT00119457], which is a phase II proof-of-concept clinical trial to determine the safety and efficacy of TTP889 for the prevention of venous thromboembolism in patients with total hip replacement surgery. It has not yet been tested in patients with AF.
Future developments
The emerging oral anticoagulant agents are target selective. They have predictable pharmacokinetic and pharmacodynamic parameters and do not need routine monitoring. They are not associated with significant food and drug interactions, and can be administered in simple fixed daily or twice daily doses. Among numerous drug candidates under clinical development, two orally active anticoagulants, dabigatran etexilate, a DTI, and rivaroxaban, a direct FXa inhibitor, are in the most advanced stages of development and may allow a paradigm shift in anticoagulation for AF in the future. A choice of agents will allow individualization of therapy. Whether these drugs have possible pleiotropic effects, as seen with heparins, remains to be seen, in addition to whether there are inherent antithrombotic advantages with FXa versus Factor IIa inhibition. Mechanistically, neither agent has been compared head to head for superiority. Eventually, head-to-head trials comparing FXaI with a DTI will be needed to identify the optimal anticoagulant. The safety, efficacy, ease of use and cost will determine the superiority or noninferiority of one agent over another.
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